- Home
- DNLI vs CNTA Comparison
DNLI vs CNTA Comparison
Compare DNLI & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNLI
- CNTA
- Stock Information
- Founded
- DNLI 2013
- CNTA 2020
- Country
- DNLI United States
- CNTA United Kingdom
- Employees
- DNLI N/A
- CNTA N/A
- Industry
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- DNLI Health Care
- CNTA Health Care
- Exchange
- DNLI Nasdaq
- CNTA Nasdaq
- Market Cap
- DNLI 1.9B
- CNTA 1.8B
- IPO Year
- DNLI 2017
- CNTA 2021
- Fundamental
- Price
- DNLI $14.37
- CNTA $12.30
- Analyst Decision
- DNLI Strong Buy
- CNTA Strong Buy
- Analyst Count
- DNLI 15
- CNTA 10
- Target Price
- DNLI $33.92
- CNTA $26.11
- AVG Volume (30 Days)
- DNLI 1.4M
- CNTA 628.0K
- Earning Date
- DNLI 05-06-2025
- CNTA 05-20-2025
- Dividend Yield
- DNLI N/A
- CNTA N/A
- EPS Growth
- DNLI N/A
- CNTA N/A
- EPS
- DNLI N/A
- CNTA N/A
- Revenue
- DNLI N/A
- CNTA N/A
- Revenue This Year
- DNLI N/A
- CNTA N/A
- Revenue Next Year
- DNLI $384.25
- CNTA N/A
- P/E Ratio
- DNLI N/A
- CNTA N/A
- Revenue Growth
- DNLI N/A
- CNTA N/A
- 52 Week Low
- DNLI $10.57
- CNTA $7.75
- 52 Week High
- DNLI $33.33
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- DNLI 46.97
- CNTA 40.97
- Support Level
- DNLI $13.36
- CNTA $11.88
- Resistance Level
- DNLI $16.97
- CNTA $14.39
- Average True Range (ATR)
- DNLI 0.95
- CNTA 0.79
- MACD
- DNLI -0.06
- CNTA -0.00
- Stochastic Oscillator
- DNLI 28.08
- CNTA 18.68
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.